20/20 Biolabs, Inc.

https://2020biolabs.com

20/20 Biolabs, Inc. is a commercial-stage diagnostics company dedicated to developing and commercializing AI-powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company's core mission is to leverage machine learning and real-world data to enhance diagnostic accuracy and clinical utility. Headquartered in Gaithersburg, Maryland, 20/20 Biolabs operates a CAP-accredited and CLIA-licensed laboratory.

The company offers two primary product lines under its OneTest brand: OneTest for Cancer and OneTest for Longevity. OneTest for Cancer is a multi-cancer early detection (MCED) blood test that utilizes a protein tumor marker approach to detect various cancers, including lung, pancreatic, ovarian, and liver, at earlier stages. It is designed for convenient at-home collection. OneTest for Longevity, anticipated to launch in the first half of 2026, measures inflammatory biomarkers associated with chronic conditions such as heart disease, cancers, dementia, diabetes, and mental health.

20/20 Biolabs began trading on the Nasdaq Capital Market under the ticker symbol AIDX on February 19, 2026. Recent developments include a partnership with Evexia Diagnostics in April 2026 to make OneTest for Cancer available to Evexia's network of over 40,000 practitioners, and an exclusive U.S. license agreement with ROKIT Healthcare in March 2026 to integrate advanced chronic kidney disease prediction technology into its Longevity Test Program. The company reported a 17% increase in full-year 2025 revenue to $2.0 million and secured a contingent financing agreement for up to $40 million. Jonathan Cohen serves as the President and CEO.

Latest updates

20/20 BioLabs Gains Distribution Via Evexia's Functional Medicine Network

Event summary

  • 20/20 BioLabs’ OneTest™ for Cancer is now available through Evexia Diagnostics’ platform.
  • Evexia’s network comprises approximately 40,000 functional and integrative medicine practitioners.
  • Evexia Diagnostics was founded in 2007 and caters to the Functional and Integrative Medicine communities.
  • 20/20 BioLabs’ OneTest™ for Longevity is expected to launch in the first half of 2026.

The big picture

This partnership represents a strategic effort by 20/20 BioLabs to expand the reach of its OneTest™ platform beyond direct sales, leveraging Evexia’s established network within the functional and integrative medicine space. The functional medicine sector, while niche, is experiencing growth as patients seek more personalized and preventative healthcare solutions. This deal underscores the increasing importance of distribution networks in the diagnostics space, particularly for novel, AI-powered testing solutions.

What we're watching

Adoption Rate
The speed at which Evexia’s practitioner network integrates OneTest™ into patient care workflows will be a key indicator of the partnership’s success and 20/20 BioLabs’ revenue growth.
Competition
The market for multi-cancer early detection tests is becoming increasingly crowded; 20/20 BioLabs must demonstrate a clear differentiation in clinical utility and cost-effectiveness to maintain market share.
Regulatory Landscape
Continued scrutiny and potential regulatory changes surrounding direct-to-consumer and at-home diagnostic testing could impact the accessibility and reimbursement of OneTest™.

20/20 BioLabs Reports Revenue Growth, Eyes Medicare Reimbursement

Event summary

  • 20/20 BioLabs reported $2.0 million in revenue for FY 2025, a 17% increase year-over-year.
  • Gross margins expanded 900 basis points to 29.6% in FY 2025, driven by higher-margin revenue streams.
  • The company secured $5.0 million in private placement funding on February 19, 2026, with potential for up to $40 million.
  • Maryland fire departments were awarded $520,000 in funding for OneTest™ MCED blood tests, representing a 225% increase in funding compared to the prior year.
  • The Medicare Multi-Cancer Early Detection Screening Act was signed into law on February 3, 2026, creating a pathway for Medicare reimbursement by 2028.

The big picture

20/20 BioLabs is positioned to capitalize on the growing demand for early cancer detection, fueled by both patient interest and regulatory tailwinds. The company's focus on AI-powered diagnostics and partnerships with established players like IBM and ROKIT Healthcare offers a differentiated approach. However, the company's reliance on state and federal funding, coupled with its current cash balance, presents a significant risk if adoption rates fail to meet expectations.

What we're watching

Regulatory Landscape
The timeline for Medicare coverage of OneTest™ for Cancer will be critical; delays could significantly impact revenue projections.
Financial Discipline
Whether 20/20 BioLabs can sustain its reduced operating expense base as it scales will determine its path to profitability.
Partnership Risk
The success of the ROKIT Healthcare partnership in expanding into East Asia will be a key indicator of the company's international growth potential.

Maryland Firefighter Screening Grant Boosts 20/20 BioLabs' Early Detection Push

Event summary

  • Maryland awarded $520,000 to 18 fire departments for cancer screenings using 20/20 BioLabs’ OneTest™.
  • The grant represents a 225% increase in funding compared to the previous year.
  • Approximately 1,400 firefighters are expected to be screened in April/May 2026.
  • The Salisbury Fire Department has administered nearly 300 screenings over the past three years.
  • Congress passed legislation in March 2026 establishing a pathway for Medicare coverage of MCEDs beginning in 2028.

The big picture

The Maryland grant program underscores a growing trend of public sector investment in early cancer detection technologies, particularly for high-risk occupational groups like firefighters. This initiative, coupled with the impending Medicare pathway, represents a significant potential revenue stream for 20/20 BioLabs, but also highlights the challenges of navigating a complex regulatory environment and scaling production to meet demand. The company's differentiation through protein tumor markers and AI, as opposed to DNA-based approaches, positions it uniquely, but also requires demonstrating clear clinical and economic advantages.

What we're watching

Regulatory Headwinds
The success of 20/20 BioLabs’ Medicare coverage application will hinge on demonstrating clinical utility and cost-effectiveness, a process complicated by the relatively new nature of MCED testing.
Execution Risk
The company's ability to scale its testing capacity to meet the demand from the grant program and potential future state-level initiatives will be a key determinant of revenue growth.
Governance Dynamics
The proliferation of state-level firefighter cancer screening programs could create a fragmented reimbursement landscape, potentially impacting 20/20 BioLabs’ pricing and market access strategy.

20/20 BioLabs Integrates CKD Prediction Tech, Eyes Korean Expansion

Event summary

  • 20/20 BioLabs (Nasdaq: AIDX) licensed ROKIT Healthcare’s chronic kidney disease (CKD) prediction algorithm to integrate into its OneTest for Longevity platform.
  • ROKIT will receive a royalty on net sales and will reimburse 20/20 for one-third of mutually agreed sales and marketing expenses.
  • The companies are negotiating a potential agreement for ROKIT to commercialize 20/20’s longevity platform in Korea and other East Asian markets.
  • The integration aims to enhance therapeutic outcomes by correlating biomarker tracking with 3-D bio-printed therapies for conditions like burns and CKD.
  • The CKD market in the US is estimated at over 35 million individuals, representing a significant potential expansion for 20/20’s testing services.

The big picture

This agreement signals a growing convergence of predictive analytics and regenerative medicine, as companies seek to personalize treatment and improve patient outcomes. 20/20’s strategy of integrating biomarker tracking into longevity testing positions it within a burgeoning market, but the partnership’s financial structure introduces a layer of complexity that warrants close monitoring. The potential Korean expansion represents a significant opportunity, but also exposes 20/20 to new geopolitical and regulatory risks.

What we're watching

Geographic Expansion
The success of potential commercialization in Korea and East Asia will depend on navigating regulatory hurdles and adapting the OneTest platform to local healthcare systems.
Clinical Validation
The claimed synergistic effect of biomarker tracking and 3-D bio-printed therapies requires robust clinical validation to drive adoption and demonstrate tangible patient outcomes.
Sales Execution
20/20’s ability to effectively market and sell the expanded OneTest, particularly given the royalty/reimbursement structure with ROKIT, will be a key determinant of financial performance.

Protein Biomarker Tests Gain Ground as Early Cancer Detection Debate Intensifies

Event summary

  • 20/20 BioLabs highlighted advantages of its patented protein tumor marker (PTM) technology for multi-cancer early detection, positioning it as a potential alternative to circulating tumor DNA (ctDNA) tests.
  • Recent studies, including a large-scale U.K. trial, have raised questions about the limitations of ctDNA-based MCEDs in detecting early-stage cancers.
  • 20/20 BioLabs’ OneTest for Cancer (Premium version) demonstrated a 50% detection rate for early-stage cancers like pancreatic and ovarian cancer in a blinded cohort.
  • A multicenter study published in Nature’s Precision Oncology showed consistent cancer signal detection across diverse populations using an AI-enhanced blood test integrating seven protein tumor markers.
  • Congress passed legislation in February 2026 creating a pathway for Medicare coverage of MCEDs beginning in 2028.

The big picture

The debate around the optimal approach to multi-cancer early detection is intensifying, with ctDNA facing biological limitations in early-stage disease. 20/20 BioLabs is positioning its protein biomarker technology as a complementary or alternative solution, capitalizing on a growing market driven by recent legislative changes and a desire for more effective screening tools. The company's success hinges on demonstrating superior clinical utility and securing favorable reimbursement pathways.

What we're watching

Regulatory Landscape
The implementation of Medicare coverage for MCEDs will significantly impact adoption rates and reimbursement models, potentially favoring technologies with demonstrated early-stage detection capabilities.
Competitive Dynamics
How 20/20 BioLabs will navigate the evolving competitive landscape, particularly as other companies refine ctDNA-based tests and explore hybrid approaches, will determine its market share.
Clinical Adoption
The pace at which clinicians integrate protein biomarker-based tests into screening protocols, and patient acceptance of tiered testing approaches, will influence the commercial success of OneTest.

20/20 BioLabs Launches AI-Powered Longevity Test, Eyes Chronic Disease Market

Event summary

  • 20/20 BioLabs (AIDX) launched 'OneTest for Longevity,' a blood test assessing chronic disease risk, integrating inflammatory biomarkers, dietary habits, and scientific research.
  • The solution leverages IBM's watsonx.ai platform and DAISource's expertise for AI-driven data analysis and personalized health insights.
  • The test utilizes curated scientific publications from the University of South Carolina’s Dietary Inflammatory Index (DII®).
  • 20/20 BioLabs began trading on Nasdaq on February 19, 2026, under the ticker symbol 'AIDX'.

The big picture

20/20 BioLabs' entry into the longevity testing market reflects the growing consumer interest in preventative health and personalized wellness solutions. The partnership with IBM and DAISource highlights the increasing integration of AI in healthcare diagnostics, but also introduces complexities around data privacy, algorithmic bias, and regulatory oversight. The company's CLIAx service also positions it as a potential facilitator for other diagnostics startups, creating a unique, albeit potentially risky, business model.

What we're watching

Regulatory Scrutiny
The lack of FDA approval for OneTest for Longevity as an LDT exposes the company to potential regulatory challenges and limitations on marketing claims, particularly as the direct-to-consumer testing market matures.
Adoption Rate
The success of OneTest hinges on consumer adoption and willingness to pay for longevity-focused testing, which remains a nascent market and may require significant education and marketing investment.
AI Dependency
20/20 BioLabs’ reliance on IBM’s watsonx.ai platform creates a vendor dependency that could impact pricing, scalability, and the company’s ability to innovate independently.

20/20 BioLabs Debuts on Nasdaq, Schedules Investor Webinar

Event summary

  • 20/20 BioLabs (AIDX) began trading on Nasdaq February 19, 2026.
  • The company will host a virtual investor webinar on February 26, 2026, at 2:00 p.m. Eastern Time.
  • CEO Jonathan Cohen will lead the webinar to discuss the Nasdaq listing, OneTest™ for Cancer, and OneTest for Longevity (expected launch before end of February).
  • The company offers MCED and longevity blood tests accessible via at-home collection devices.
  • 20/20 BioLabs operates a CAP-accredited, CLIA-licensed laboratory in Gaithersburg, MD.

The big picture

20/20 BioLabs’ Nasdaq listing marks a significant milestone as it seeks to capitalize on the growing demand for early disease detection and preventative healthcare. The company’s focus on AI-powered diagnostics and at-home testing positions it within a competitive landscape, requiring robust clinical validation and effective marketing to achieve widespread adoption. The CLIAx model, while innovative, presents a unique operational challenge requiring careful management to ensure profitability.

What we're watching

Market Adoption
The success of OneTest for Longevity will hinge on demonstrating tangible health benefits and convincing consumers to adopt regular biomarker testing, a relatively nascent market.
Regulatory Scrutiny
As a leader in MCED, 20/20 BioLabs will likely face increasing regulatory scrutiny regarding test accuracy, clinical validation, and patient data privacy, potentially impacting commercialization timelines.
CLIAx Sustainability
The long-term viability of the Clinical Laboratory Innovation Accelerator (CLIAx) depends on attracting a consistent flow of overseas diagnostics startups and generating sufficient revenue to offset operational costs.

20/20 BioLabs Goes Public via Direct Listing, Secures Contingent $40M Funding

Event summary

  • 20/20 BioLabs began trading on the Nasdaq under the ticker symbol 'AIDX' on February 19, 2026.
  • The company entered into a contingent financing agreement for up to $40 million, with $5 million expected to close immediately.
  • 20/20 BioLabs is focused on AI-powered blood tests for cancer and longevity, including the OneTest™ for Cancer™ and the upcoming OneTest for Longevity™.
  • Congress recently passed legislation potentially paving the way for Medicare reimbursement for multi-cancer early detection tests by 2028.

The big picture

20/20 BioLabs' direct listing and contingent funding reflect growing investor interest in AI-driven diagnostics and preventative healthcare. The company's focus on accessible, at-home testing positions it to capitalize on a shift towards early detection and lifestyle-based disease management, potentially disrupting traditional treatment paradigms. The contingent financing, while providing a near-term boost, introduces a performance-based risk that will be closely scrutinized by investors.

What we're watching

Funding Execution
The company's ability to meet the performance metrics required to unlock the full $40 million in contingent funding will be a key indicator of its operational effectiveness and market traction.
Reimbursement Landscape
The impact of the new legislation on Medicare reimbursement for MCEDs will significantly influence the adoption rate and revenue potential of OneTest™ for Cancer™.
Competitive Dynamics
The success of 20/20 BioLabs’ lower-priced MCED offering relative to competitors utilizing ctDNA technology will determine its market share and long-term viability.
CID: 685